- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CHINA YONGXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 36,350 | 0,00 % | IONIS PHARMACEUTICALS INC - 8-K, Current Report | ||
| CSPC PHARMA | 0,580 | -1,02 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYH2062 INJECTION (SIRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL | ||
| ACADIA PHARMACEUTICALS | 17,390 | +1,87 % | Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview | SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.
"The success of Acadia's two growing... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,010 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia | - Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis - - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 313,98 | 0,00 % | Arrowhead Pharma und Madrigal gehen steil: Zwischen Adipositas- und Übernahmefantasie | Die Biotechnologie-Branche bietet viele spannende Storys. Einen aussichtsreichen Aktienkorb mit 14 verschiedenen Titeln bildet der Biotech Supertrends Index ab. Zuletzt sorgten im Index vor allem die... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,930 | +1,43 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan | CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| OPUS GENETICS | 1,070 | 0,00 % | Opus Genetics, Inc.: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy | Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,146 | +20,66 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| VIRACTA THERAPEUTICS | 0,239 | 0,00 % | Viracta Therapeutics Engages In Strategic Alternatives, Closes NAVAL-1 Trial | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R) | Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 3,280 | +2,50 % | Savara (NASDAQ:SVRA) Now Covered by Analysts at Wells Fargo & Company | ||
| GALECTIN THERAPEUTICS | 0,870 | 0,00 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH | In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value While there was a favorable trend for incidence of varices in the primary end point intent-to-treat... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 4,700 | +10,07 % | Biodexa Pharmaceuticals PLC: Result of General Meeting | November 22, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Result of General Meeting Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ: BDRX), a clinical stage biopharmaceutical... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | SCICLONE PHARMA (06600): (1) PROPOSAL FOR THE PRIVATISATION OF SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED BY SILVER PEGASUS INVESTMENT LIMITED BY WAY ... | ||
| NOVABAY PHARMACEUTICALS | 0,080 | 0,00 % | NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results | EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024.
"Avenova sales through... ► Artikel lesen |
Das Unternehmen CHINA YONGXIN PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHINA YONGXIN PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
